Circulating RNA Signatures for Early Preeclampsia Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biomarkers for preeclampsia lack discriminative and predictive power for early detection and risk assessment, posing a significant risk for both mother and baby due to the severity and timing of the condition.
Innovation Solution
Identifying a panel of circulating RNA (C-RNA) molecules encoding specific proteins, such as ARRDC2, JUN, SKIL, and others, through methods like hybridization, RT-PCR, or sequencing, to detect preeclampsia and assess risk by obtaining, purifying, and analyzing RNA from biosamples, removing cell-free DNA, and enriching for protein-coding sequences.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If protein biomarkers are used for preeclampsia detection, then detection can be performed in maternal serum, but the biomarkers lack discriminative and predictive power
Solution Approach 1:
The patent segments the detection approach by switching from protein biomarker analysis to circulating RNA molecule analysis. Specifically, it identifies and measures specific C-RNA molecules (such as those encoding PAPPA2, PLAC8, and LEP) that are more discriminative and predictive for preeclampsia risk assessment than traditional protein biomarkers.
Solution Approach 2:
The patent changes the detection parameter from protein concentration levels to circulating RNA molecule presence and quantity. This parameter change enables early detection at presymptomatic stages with higher accuracy, as C-RNA molecules provide better discriminative power for distinguishing preeclampsia risk from normal pregnancy states.
2Loss of time
If early detection methods are implemented, then timely intervention is possible, but current methods lack sufficient predictive power
Solution Approach 1:
The patent enables preliminary detection of preeclampsia risk at presymptomatic stages by measuring circulating RNA molecules before clinical symptoms appear. This preliminary action allows timely intervention while maintaining high predictive power, as the C-RNA biomarkers (such as PAPPA2 and PLAC8 transcripts) are detectable and discriminatory before disease manifestation.
3Reliability
If a comprehensive panel of C-RNA molecules is analyzed, then detection accuracy improves, but method complexity increases
Solution Approach 1:
The patent extracts and focuses on specific circulating RNA molecules from the complex maternal serum environment. By targeting particular C-RNA molecules (such as those encoding PAPPA2, PLAC8, LEP, and other placental-derived RNAs), the method achieves high detection accuracy while managing complexity through selective measurement rather than comprehensive analysis of all RNA species.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides a robust and discriminative method for early detection and risk assessment of preeclampsia, enabling timely intervention and reducing maternal and fetal complications.
Implementation Method 1
identifying protein coding sequences encoded by the C-RNA molecules within the biosample includes hybridization, reverse transcriptase PCR, microarray chip analysis, or sequencing
Data Source
AI summary
The present invention includes methods and materials for use in the detection preeclampsia and/or determining an increased risk for preeclampsia in a pregnant female, the method including identifying in a biosample obtained from the pregnant women a plurality of circulating RNA (C-RNA) molecules.